Equities research analysts predict that NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Rating) will post ($0.27) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for NeuBase Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.25). NeuBase Therapeutics posted earnings per share of ($0.29) in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.9%. The company is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that NeuBase Therapeutics will report full year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.15) to ($0.89). For the next financial year, analysts forecast that the business will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.31) to ($0.99). Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for NeuBase Therapeutics.
A number of brokerages recently issued reports on NBSE. Zacks Investment Research downgraded NeuBase Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Chardan Capital lowered their price target on NeuBase Therapeutics from $18.00 to $9.00 in a research report on Friday, May 13th.
NBSE traded down $0.01 during mid-day trading on Friday, reaching $1.00. 200 shares of the company traded hands, compared to its average volume of 81,391. The stock has a market capitalization of $32.26 million, a P/E ratio of -0.96 and a beta of 0.79. The company’s fifty day moving average price is $1.49 and its 200-day moving average price is $2.06. NeuBase Therapeutics has a 52-week low of $0.89 and a 52-week high of $5.51.
NeuBase Therapeutics Company Profile (Get Rating)
NeuBase Therapeutics, Inc, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.
- Get a free copy of the StockNews.com research report on NeuBase Therapeutics (NBSE)
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.